share_log

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Market Cap Dropped CN¥372m Last Week; Individual Investors Bore the Brunt

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) Market Cap Dropped CN¥372m Last Week; Individual Investors Bore the Brunt

上周,莎普爱思(股票代码:603168)的市值下降了37200万人民币,个人投资者承受了主要压力。
Simply Wall St ·  08/23 01:47

Key Insights

主要见解

  • Significant control over Zhejiang Shapuaisi PharmaceuticalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 6 investors have a majority stake in the company with 51% ownership
  • Insiders own 24% of Zhejiang Shapuaisi PharmaceuticalLtd
  • 个人投资者对浙江莎普爱思制药有限公司的重要控制意味着公众在管理和治理相关决策中拥有更多的影响力。
  • 6个投资者拥有51%的普通股份。
  • 内部人持有浙江莎普爱思制药有限公司24%的股权。

To get a sense of who is truly in control of Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are individual investors with 45% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

为了了解浙江莎普爱思制药有限公司(上海证券交易所:603168)真正的控制者是谁,了解其业务的所有权结构至关重要。持有公司45%股权的个人投资者占据了最大的份额。换句话说,该群体在投资公司方面获得(或失去)的最多。

While insiders, who own 24% shares weren't spared from last week's CN¥372m market cap drop, individual investors as a group suffered the maximum losses

尽管持有24%股份的内部人员在上周遭受到了37200万人民币的市值下跌,但作为一个群体,个人投资者遭受了最大的损失

In the chart below, we zoom in on the different ownership groups of Zhejiang Shapuaisi PharmaceuticalLtd.

在下面的图表中,我们放大了浙江莎普爱思医药股份有限公司不同的所有权群体

1724392061502
SHSE:603168 Ownership Breakdown August 23rd 2024
SHSE:603168所有权分布图 2024年8月23日

What Does The Institutional Ownership Tell Us About Zhejiang Shapuaisi PharmaceuticalLtd?

机构持股情况可以告诉我们关于浙江莎普爱思医药股份有限公司的一些信息

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。

We can see that Zhejiang Shapuaisi PharmaceuticalLtd does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zhejiang Shapuaisi PharmaceuticalLtd's earnings history below. Of course, the future is what really matters.

我们可以看到浙江莎普爱思医药股份有限公司确实有机构投资者,并且他们持有公司股份的一部分。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这个事实,因为机构有时也会做出糟糕的投资,就像每个人都会一样。如果多个机构同时改变对某只股票的观点,你可能会看到股价快速下跌。因此,值得看一下浙江莎普爱思医药股份有限公司的盈利历史。当然,未来才是真正重要的。

1724392062554
SHSE:603168 Earnings and Revenue Growth August 23rd 2024
SHSE:603168 指数和营业收入增长2024年8月23日

Hedge funds don't have many shares in Zhejiang Shapuaisi PharmaceuticalLtd. Looking at our data, we can see that the largest shareholder is Shanghai Yanghe Industrial Co., Ltd. with 21% of shares outstanding. In comparison, the second and third largest shareholders hold about 12% and 9.2% of the stock.

对冲基金没有持有浙江莎普爱思制药有限公司的股份。根据我们的数据,我们可以看到最大的股东是上海洋河实业有限公司,持有21%的股份。相比之下,第二和第三大股东持有约12%和9.2%的股份。

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪也是有意义的,以知道风向如何。就我们所知,目前并没有该公司的分析师覆盖。因此,可能被忽略了。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

虽然研究公司的机构所有权数据是有意义的,但考虑到分析师的看法,了解风向也是有意义的。我们的信息表明,该股票没有任何分析师的覆盖,因此它可能鲜为人知。

Insider Ownership Of Zhejiang Shapuaisi PharmaceuticalLtd

莎普爱思制药有限公司内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同国家,内部人员的定义可能会略有不同,但董事会成员始终是内部人员。管理层最终向董事会负责。然而,如果管理人员是创始人或CEO,那么成为执行董事会成员也是很常见的。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。

Our most recent data indicates that insiders own a reasonable proportion of Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.. Insiders have a CN¥576m stake in this CN¥2.4b business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

根据我们最新的数据显示,内部人员在浙江莎普爱思制药有限公司持有合理比例的股份。内部人员在这家价值24亿元的企业中持有57600万人民币的股份。这可能意味着创始人仍然拥有大量股份。您可以点击这里查看他们是否一直在买卖股票。

General Public Ownership

一般大众所有权

With a 45% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Zhejiang Shapuaisi PharmaceuticalLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

个人投资者主要由普通大众组成,拥有45%的股权,对于浙江莎普爱思制药有限公司有一定的影响力。虽然这样的所有权规模相当可观,但如果决策与其他大股东不一致,可能无法改变公司政策。

Private Company Ownership

私有公司的所有权

We can see that Private Companies own 23%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我们可以看到私人公司拥有股份表决的23%。仅靠这个事实很难得出结论,因此值得研究谁拥有那些私人公司的股份。有时内部人员或其他相关方可能通过单独的私人公司利益持有公共公司的股份。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Zhejiang Shapuaisi PharmaceuticalLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Zhejiang Shapuaisi PharmaceuticalLtd , and understanding them should be part of your investment process.

始终值得考虑在一家公司中持有股份的不同群体。 但是,要更好地了解浙江莎普爱思医药有限公司,我们需要考虑许多其他因素。 例如,考虑投资风险的永久幽灵。 我们已经确定了浙江莎普爱思医药有限公司的1个警示信号,并且了解这些信号应该是您投资过程的一部分。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

当然,这也可能不是最好的股票交易。因此,您可能想看看我们免费的潜力股票收藏,这些股票具有有利的财务状况。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发